MKI67 and ovarian carcinoma: As shown in Figure 2E, the immunofluorescence intensity of Ki-67 was significantly decreased in the AZD4547-treated group compared with that in the control group, thereby confirming the antiproliferative effect of AZD4547 in ovarian cancer cells.